| Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque … E Bezard, S Dovero, C Prunier, P Ravenscroft, S Chalon, D Guilloteau, ... Journal of Neuroscience 21 (17), 6853-6861, 2001 | 591 | 2001 |
| Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease PJ Hallett, AW Dunah, P Ravenscroft, S Zhou, E Bezard, AR Crossman, ... Neuropharmacology 48 (4), 503-516, 2005 | 218 | 2005 |
| Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive … W Meissner, P Ravenscroft, R Reese, D Harnack, R Morgenstern, ... Neurobiology of disease 22 (3), 586-598, 2006 | 158 | 2006 |
| Calcium‐permeable AMPA receptors are involved in the induction and expression of l‐DOPA‐induced dyskinesia in Parkinson’s disease C Kobylecki, MA Cenci, AR Crossman, P Ravenscroft Journal of neurochemistry 114 (2), 499-511, 2010 | 122 | 2010 |
| The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP … JE Nash, P Ravenscroft, S McGuire, AR Crossman, FS Menniti, ... Experimental neurology 188 (2), 471-479, 2004 | 119 | 2004 |
| Striatal histone modifications in models of levodopa‐induced dyskinesia AP Nicholas, FD Lubin, PJ Hallett, P Vattem, P Ravenscroft, E Bezard, ... Journal of neurochemistry 106 (1), 486-494, 2008 | 116 | 2008 |
| Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate Q Barraud, I Obeid, I Aubert, G Barrière, H Contamin, S McGuire, ... PloS one 5 (10), e13306, 2010 | 103 | 2010 |
| Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic non-human primates: P56 A Nadjar, J Brotchie, C Guigoni, Q Li, S Zhou, G Wang, P Ravenscroft, ... Movement Disorders 21, 2006 | 100* | 2006 |
| Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia A Nadjar, JM Brotchie, C Guigoni, Q Li, SB Zhou, GJ Wang, P Ravenscroft, ... Journal of Neuroscience 26 (34), 8653-8661, 2006 | 100 | 2006 |
| Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease MP Hill, P Ravenscroft, E Bezard, AR Crossman, JM Brotchie, A Michel, ... Journal of Pharmacology and Experimental Therapeutics 310 (1), 386-394, 2004 | 87 | 2004 |
| Synaptic recruitment of AMPA glutamate receptor subunits in levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate MA Silverdale, C Kobylecki, PJ Hallett, Q Li, AW Dunah, P Ravenscroft, ... Synapse 64 (2), 177-180, 2010 | 85 | 2010 |
| Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia P Ravenscroft, S Chalon, JM Brotchie, AR Crossman Experimental neurology 185 (1), 36-46, 2004 | 81 | 2004 |
| Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys E Bezard, P Ravenscroft, CE Gross, AR Crossman, JM Brotchie Neurobiology of disease 8 (2), 343-350, 2001 | 72 | 2001 |
| Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit KL Eskow Jaunarajs, DG Standaert, TX Viegas, MD Bentley, Z Fang, ... Movement Disorders 28 (12), 1675-1682, 2013 | 69 | 2013 |
| Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys PO Fernagut, Q Li, S Dovero, P Chan, T Wu, P Ravenscroft, M Hill, Z Chen, ... PloS one 5 (11), e14053, 2010 | 65 | 2010 |
| Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease C Kobylecki, MP Hill, AR Crossman, P Ravenscroft Movement disorders 26 (13), 2354-2363, 2011 | 62 | 2011 |
| Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate MA Silverdale, SL Nicholson, P Ravenscroft, AR Crossman, MJ Millan, ... Experimental neurology 188 (1), 128-138, 2004 | 59 | 2004 |
| NMDA receptors in the basal ganglia P RAVENSCROFT, J BROTCHIE Journal of Anatomy 196 (4), 577-585, 2000 | 58 | 2000 |
| Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease D Scheller, P Chan, Q Li, T Wu, R Zhang, L Guan, P Ravenscroft, ... Experimental neurology 203 (2), 415-422, 2007 | 51 | 2007 |
| Pattern of levodopa‐induced striatal changes is different in normal and MPTP‐lesioned mice CE Gross, P Ravenscroft, S Dovero, M Jaber, B Bioulac, E Bezard Journal of neurochemistry 84 (6), 1246-1255, 2003 | 48 | 2003 |
